BioInvent signs Licensing Agreement with Mitsubishi Tanabe Pharma for the Discovery and Development of Therapeutic Antibodies

04-Aug-2009 - Sweden

BioInvent International AB announces that it has signed a license agreement with Mitsubishi Tanabe Pharma Corporation for the development of antibodies, up to five therapeutic targets, from BioInvent’s n-CoDeR® library. Under the terms of the agreement, Mitsubishi Tanabe will be granted access to BioInvent’s discovery and development technology platform.

BioInvent will receive an undisclosed upfront access fee, annual maintenance fees as well as royalties on commercialised products and success-based milestone payments. The agreement follows on an existing research license and a feasibility study concluded earlier this year.

The n-CoDeR® library contains more than 20 billion highly diverse, fully human antibody fragments that have been created using BioInvent’s patented approach, generating antibodies with high affinity and selectivity.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous